Recently, the registration status of Jiudian Hongyang's pharmaceutical excipient Crotamiton (F20220000469) achieved a registration status changed from "I" to "A" at the CDE of the NMPA, and it successfully passed the review and was approved for marketing.

As a pharmaceutical excipient, crotamiton can be used as a dissolving agent and permeation enhancer in multiple topical preparations such as loxoprofen sodium, indomethacin, difluprednate, ketoconazole, flurbiprofen, triamcinolone acetonide, etc. Its unique chemical structure can not only effectively enhance the permeability and absorption rate of the drug, but also significantly improve the patient's experience. At the same time, crotamiton has a mild local anesthetic effect and can treat various types of pruritus; it has a specific killing effect on scabies and can act on the nervous system of scabies, thereby paralyzing and killing scabies; in addition, it also has an inhibitory effect on the growth of streptococci and staphylococci.

With the rapid development of the pharmaceutical industry, the role of pharmaceutical excipients in drug research,development and treatment has become increasingly prominent. The approval of crotamiton has further enriched the company's product line of external preparation excipients. Jiudian Hongyang will continue to work hard and continuously provide more high-quality raw and excipient products and services to various preparation companies.